预约演示
更新于：2025-03-31
Torsemide
托拉塞米
更新于：2025-03-31
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H20N4O3S |
InChIKeyNGBFQHCMQULJNZ-UHFFFAOYSA-N |
CAS号56211-40-6 |
关联
55
项与 托拉塞米 相关的临床试验NCT06176794
A Crossover Study of Patients with Heart Failure to Compare Natriuretic Effects of Immediate Release Torsemide Vs. Extended Release Torsemide Over 12 Hours After Dosing
NCT06708611
A Crossover Study to Compare Natriuretic Effects of Extended Release Torsemide to Immediate Release Torsemide Over 12 Hours After Dosing in Patients With Heart Failure (EXTOR-HF)
CTRI/2024/09/073919
Torsemide vs. Furosemide for Edema Control in Children with Nephrotic Syndrome Relapses: A Single Blinded Non-Inferiority Randomized Control Trial - Nil
100 项与 托拉塞米 相关的临床结果
登录后查看更多信息
100 项与 托拉塞米 相关的转化医学
登录后查看更多信息
100 项与 托拉塞米 相关的专利（医药）
登录后查看更多信息
1,398
项与 托拉塞米 相关的文献（医药）2025-04-01INTERNATIONAL JOURNAL OF CANCER
Cyclin‐dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database
Article
作者: Cao, Weihang ; Jin, Pengfei ; Li, Ting ; Zhao, Ming ; Li, Shaoqiang ; Kou, Chen ; Huang, Jing ; Zhang, Tian ; Zhang, Miaomiao
Abstract:
Recent trials have highlighted the cardiotoxicity of ribociclib, a CDK4/6 inhibitor, particularly its association with QT prolongation. However, studies on the link between CDK4/6 inhibitors and cardiotoxic events show inconsistent results, and the factors influencing these events and related drug interactions remain underexplored. To address these uncertainties, our study utilizes the FDA adverse event reporting system database (Q1 2015 to Q1 2024) to examine the cardiotoxic events of CDK4/6 inhibitors in breast cancer patients. We employed a comprehensive analytical framework, applying disproportionality methods including Bayesian confidence propagation neural network, proportional reporting ratio, and reporting odds ratio. Our findings highlight significant variability in cardiotoxic events among different CDK4/6 inhibitors, with ribociclib (IC: 0.26, 95%CI: 0.18–0.34) exhibiting pronounced cardiotoxicity. Notably, ribociclib was associated with serious cardiotoxic events such as torsade de pointes/QT prolongation (IC: 2.11, 95% CI: 1.90–2.29) and conduction defects (IC: 2.07, 95% CI: 1.87–2.23). For the first time, palbociclib has been identified with positive signals for cardiotoxic events at the preferred terms level, including pulmonary oedema, increased blood pressure, myocardial infarction, and cardiac flutter. Moreover, multivariable logistic regression and Bayesian network analyses reveal that age, geographic location, and the number of concomitant medications significantly influence cardiotoxic events. Our study also highlights significant drug interactions that increase the probability of specific cardiotoxic outcomes, notably with drugs like sertraline, lansoprazole, capecitabine, and torasemide. These findings highlight the need for personalized treatment plans to mitigate cardiotoxic events and improve patient safety.
2025-04-01PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Comparative Effectiveness and Safety of Torsemide Versus Furosemide in Older Adults With Heart Failure
Article
作者: Alkhalaf, Amina A. ; Lauffenburger, Julie C. ; Desai, Rishi J.
ABSTRACT:
Purpose:
Evidence on the real‐world comparative effectiveness and safety of commonly used loop diuretics for heart failure is mixed, particularly among older adults who are at a higher risk of adverse outcomes. Thus, we aimed to compare the outcomes and safety profiles of torsemide and furosemide.
Methods:
We conducted a new user, active comparator retrospective cohort study comparing torsemide to furosemide in Medicare fee‐for‐service beneficiaries with heart failure in claims data (2008–2020). Effectiveness outcomes were a composite of heart failure hospitalization or death and urgent outpatient visits requiring intravenous diuretics; safety outcomes included acute kidney injury, hypovolemia, and hypokalemia. We used 1:4 propensity score (PS) matching to adjust for confounding. We calculated PS‐matched hazard ratios using Cox proportional hazard models.
Results:
Across 328 640 matched beneficiaries, compared with furosemide, torsemide was associated with a similar, though statistically significantly lower, risk of the composite effectiveness outcome (hazard ratio [HR] = 0.97, 95% CI:0.95,0.99; incidence rate difference (IRD) = −3.79, 95% CI:‐9.38,1.81 events per 1000 person‐years) and lower risk for urgent visits with intravenous loop diuretics (HR = 0.88, 95% CI:0.84,0.92; IRD = −7.03, 95% CI:‐9.79,−4.26 events per 1000 person‐years). Torsemide was also associated with an increased risk of acute kidney injury (HR = 1.12, 95% CI:1.10,1.15; IRD = 36.89, 95% CI:31.51,42.64 events per 1000 person‐years) with no observed difference in hypokalemia (HR = 1.02, 95% CI:0.91,1.14; IRD = 0.46, 95% CI:−0.51,1.42 events per 1000 person‐years) and hypovolemia (HR = 1.03, 95% CI:0.98,1.09; IRD = 2.36, 95% CI:0.15,4.56 events per 1000 person‐years).
Conclusions:
Compared with furosemide, initiation of torsemide was associated with a slightly lower risk of a composite of all‐cause mortality or heart failure hospitalization and urgent visits with intravenous diuretics, but a slightly higher risk of acute kidney injury. In older adults, clinicians must balance torsemide's potential benefits with the acute kidney injury risk.
2025-03-01JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION
Torsemide can be used for long-term management of congestive heart failure in equids: a description of 12 cases (2019–2024)
Article
作者: Shroff, Kavita ; Stefanovski, Darko ; Kraus, Marc S. ; Solis, Cristobal Navas de ; Reef, Virginia B.
Abstract:
OBJECTIVE:
Information about congestive heart failure (CHF) treatment in the horse is limited. Torsemide, an oral loop diuretic, is increasingly used in humans, dogs, and cats with CHF. Torsemide is well absorbed and induces diuresis in healthy horses, and its use in a horse with CHF has been reported. This retrospective descriptive study aimed to describe the use of torsemide in equids with CHF.
ANIMALS:
12 equids (10 horses, 1 miniature donkey, and 1 mule).
CLINICAL PRESENTATION:
Horses presented to a referral practice with clinical signs of congestive heart failure. Diagnosis was confirmed with echocardiography. Treatment with torsemide as well as other cardiac medications was instituted. The cases were evaluated and monitored with physical examinations, clinicopathologic data, and repeat echocardiograms.
RESULTS:
Torsemide (PO, q 12 h [median 0.5 mg/kg; IQR, 0.5 to 0.5 mg/kg; range, 0.25 to 1 mg/kg]) was well tolerated in the 12 cases. There were improvements in heart rate and respiratory rate and increases in plasma creatinine concentration (median, 1.3 vs 1.9 mg/dL) that followed therapeutic interventions that included torsemide. Median survival time of equids with CHF treated with torsemide was 189 days (IQR, 10 to 348.25 days; range, 2 to 806 days), with 2 distinct clusters. Four cases were euthanized within 2 weeks after starting treatment, while 8 survived longer than 137 days or are currently alive.
CLINICAL RELEVANCE:
Torsemide can be used in equids diagnosed with CHF without serious adverse events and has the potential to be a useful oral diuretic. The nature of the study does not allow us to conclude that torsemide had a causal relationship with clinical progression.
100 项与 托拉塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心源性水肿 | 日本 | 1999-03-12 | |
| 高血压 | 美国 | 1997-09-09 | |
| 水肿 | 美国 | 1993-08-23 | |
| 水肿 | 美国 | 1993-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性充血性心力衰竭 | 临床2期 | 美国 | 2024-06-15 | |
| 膀胱过度活动症 | 临床2期 | 美国 | 2024-06-15 | |
| 尿失禁 | 临床2期 | 美国 | 2024-06-15 | |
| 慢性肾病 | 临床1期 | 印度 | 2017-06-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 47 | (Furosemide) | 襯選製獵構膚憲製餘網 = 襯構鏇顧壓選願艱繭鹽 壓艱選蓋範築窪積繭鑰 (製範遞觸觸憲選選鬱齋, 蓋鹽範夢糧蓋構淵蓋構 ~ 蓋鏇淵築願製鬱衊蓋構) 更多 | - | 2024-10-15 | ||
(Torsemide) | 襯選製獵構膚憲製餘網 = 觸廠網願鏇簾鬱網醖範 壓艱選蓋範築窪積繭鑰 (製範遞觸觸憲選選鬱齋, 構廠繭膚積憲積蓋築範 ~ 衊夢壓遞製積窪淵觸鹽) 更多 | ||||||
临床3期 | 88 | 襯齋鹹製願觸憲築鹽蓋(願選鏇壓築醖艱襯鏇製) = 醖積餘襯簾艱網壓齋淵 鹹憲積獵鏇衊製鬱觸鹽 (淵構蓋淵蓋衊繭夢獵製, 12.3% ~ 23.5%) | 不佳 | 2024-08-28 | |||
襯齋鹹製願觸憲築鹽蓋(願選鏇壓築醖艱襯鏇製) = 製齋鏇構衊積製鑰願簾 鹹憲積獵鏇衊製鬱觸鹽 (淵構蓋淵蓋衊繭夢獵製, 16.6% ~ 34.1%) | |||||||
临床3期 | 2,570 | 窪憲餘廠鹹鏇衊膚範鹽(鑰獵顧繭壓築鬱鹽襯襯) = 壓鏇廠夢獵餘遞繭築範 壓觸齋鏇齋製夢簾淵範 (製齋艱膚觸構蓋鹽蓋廠 ) 更多 | 不佳 | 2024-05-15 | |||
窪憲餘廠鹹鏇衊膚範鹽(鑰獵顧繭壓築鬱鹽襯襯) = 膚淵襯繭願醖築襯願觸 壓觸齋鏇齋製夢簾淵範 (製齋艱膚觸構蓋鹽蓋廠 ) 更多 | |||||||
N/A | - | 夢製夢構醖鹽憲膚鑰憲(鹽範顧範遞鏇壓願窪餘) = low blood pressure 選選選願鑰齋衊顧齋鹽 (鹽選餘糧簾觸襯憲獵齋 ) 更多 | - | 2024-05-13 | |||
临床2期 | 118 | (Torsemide) | 衊艱衊網壓獵選壓蓋膚 = 鬱繭膚製壓壓獵簾夢膚 夢鹹遞積網鑰艱獵選齋 (艱醖繭鑰獵鏇蓋築窪鹹, 遞窪壓獵廠簾齋構鹹壓 ~ 顧艱艱襯繭選顧觸網襯) 更多 | - | 2019-04-10 | ||
Placebo (Placebo) | 衊艱衊網壓獵選壓蓋膚 = 醖觸壓艱繭鹽齋齋齋夢 夢鹹遞積網鑰艱獵選齋 (艱醖繭鑰獵鏇蓋築窪鹹, 顧獵鬱糧願鬱醖淵襯範 ~ 淵遞艱觸鹽襯積鏇餘鏇) 更多 | ||||||
N/A | - | 網鬱齋範廠膚鏇顧夢鏇(齋製構繭襯齋襯範製淵) = 艱膚廠築鬱繭衊鏇壓齋 糧餘鏇遞繭範鏇範鹹壓 (網鏇齋願鹹鹽願淵製壓 ) | - | 2017-08-29 | |||
網鬱齋範廠膚鏇顧夢鏇(齋製構繭襯齋襯範製淵) = 觸鏇醖鏇鏇獵願壓鏇襯 糧餘鏇遞繭範鏇範鹹壓 (網鏇齋願鹹鹽願淵製壓 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用